BG Medicine Welcomes Inclusion of Galectin-3 as Biomarker of Myocardial Fibrosis in 2013 ACCF/AHA Guideline for Management of Heart Failure
June 12, 2013 08:30 ET
|
BG Medicine, Inc.
WALTHAM, Mass., June 12, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today that galectin-3 testing has been recognized for the first time in the newly issued 2013 American...
BG Medicine Announces Late-Breaker Oral Presentation of New Data on the BGM Galectin-3(R) Test in Heart Failure
May 28, 2013 08:30 ET
|
BG Medicine, Inc.
WALTHAM, Mass., May 28, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced the presentation of new clinical research data on the BGM Galectin-3® test in heart disease at the...
BG Medicine, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
May 10, 2013 17:04 ET
|
BG Medicine, Inc.
WALTHAM, Mass., May 10, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, announced today...
BG Medicine Appoints Dr. Paul Sohmer as Chief Executive Officer
May 09, 2013 07:46 ET
|
BG Medicine, Inc.
WALTHAM, Mass., May 9, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, today announced...
BG Medicine Reports 2013 First Quarter Financial Results
May 09, 2013 07:45 ET
|
BG Medicine, Inc.
Abbott and bioMérieux Obtain CE Mark and Launch Galectin-3 Tests in EU
BGM Galectin-3 Revenues Coupled With Operational Discipline Drive Improved Financial Results
Q1 BGM Galectin-3 test...
Trenton Health Team Adopts Novel Diagnostic Tool, BGM Galectin-3(R) Test, to Reduce Hospital Readmissions
May 08, 2013 07:00 ET
|
BG Medicine, Inc.
TRENTON, N.J. and WALTHAM, Mass., May 8, 2013 (GLOBE NEWSWIRE) -- The Trenton Health Team (THT) and BG Medicine (Nasdaq:BGMD) today announced that THT has adopted the BGM Galectin-3® test...
BG Medicine to Announce First Quarter 2013 Financial Results and Host Conference Call on Thursday, May 9, 2013
May 02, 2013 08:30 ET
|
BG Medicine, Inc.
WALTHAM, Mass., May 2, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that the company will host a conference call and webcast on Thursday, May 9 at 8:30 a.m. Eastern...
BG Medicine Welcomes CE Mark for Galectin-3 Test
April 10, 2013 08:18 ET
|
BG Medicine, Inc.
WALTHAM, Mass., April 10, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, welcomed the...
BG Medicine Reports Fourth Quarter and Full Year 2012 Financial Results and Provides 2013 Outlook
March 13, 2013 07:45 ET
|
BG Medicine, Inc.
Q4 Revenues nearly triple from Q4 2011
Product margins increase 10% from Q4 2011
January 2013 $12.8 million public offering supplements Q4 2012 cash of $13.2 million
bioMérieux...
BG Medicine Highlights Role of Galectin-3 Testing in Combating Hospital Readmissions at the American College of Cardiology's (ACC) 62nd Annual Scientific Session & Expo
March 06, 2013 08:30 ET
|
BG Medicine, Inc.
WALTHAM, Mass., March 6, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, today announced...